Effect of gamma-vinyl GABA in tardive dyskinesia

Søren Korsgaard, Daniel Casey, Jes Gerlach

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

γ-Vinyl GABA (γ-aminobutyric acid), a drug that increases brain GABA via GABA transaminase inhibition, was evaluated in a blind, placebo-controlled trial in 10 patients with stable tardive dyskinesia. Drug effects during active treatment (2 to 6 g/day) and during pre- and posttreatment placebo periods were determined by scoring randomly sequenced videotapes of tardive dyskinesia and parkisonian symptoms recorded weekly during standardized examinations. Tardive dyskinesia was significantly reduced, and correlated to increased parkinsonism. Eye blinking rates decreased, but psychiatric symptoms were unchanged during treatment.

Original languageEnglish (US)
Pages (from-to)261-269
Number of pages9
JournalPsychiatry Research
Volume8
Issue number4
DOIs
StatePublished - 1983

Fingerprint

Vigabatrin
gamma-Aminobutyric Acid
Placebos
4-Aminobutyrate Transaminase
Aminobutyrates
Blinking
Videotape Recording
Parkinsonian Disorders
Pharmaceutical Preparations
Psychiatry
Brain
Therapeutics
Tardive Dyskinesia

Keywords

  • parkinsonism
  • tardive dyskinesia
  • γ-Vinyl GABA

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Effect of gamma-vinyl GABA in tardive dyskinesia. / Korsgaard, Søren; Casey, Daniel; Gerlach, Jes.

In: Psychiatry Research, Vol. 8, No. 4, 1983, p. 261-269.

Research output: Contribution to journalArticle

Korsgaard, S, Casey, D & Gerlach, J 1983, 'Effect of gamma-vinyl GABA in tardive dyskinesia', Psychiatry Research, vol. 8, no. 4, pp. 261-269. https://doi.org/10.1016/0165-1781(83)90014-8
Korsgaard, Søren ; Casey, Daniel ; Gerlach, Jes. / Effect of gamma-vinyl GABA in tardive dyskinesia. In: Psychiatry Research. 1983 ; Vol. 8, No. 4. pp. 261-269.
@article{d71e98a456744207a6235a22fb07ea9f,
title = "Effect of gamma-vinyl GABA in tardive dyskinesia",
abstract = "γ-Vinyl GABA (γ-aminobutyric acid), a drug that increases brain GABA via GABA transaminase inhibition, was evaluated in a blind, placebo-controlled trial in 10 patients with stable tardive dyskinesia. Drug effects during active treatment (2 to 6 g/day) and during pre- and posttreatment placebo periods were determined by scoring randomly sequenced videotapes of tardive dyskinesia and parkisonian symptoms recorded weekly during standardized examinations. Tardive dyskinesia was significantly reduced, and correlated to increased parkinsonism. Eye blinking rates decreased, but psychiatric symptoms were unchanged during treatment.",
keywords = "parkinsonism, tardive dyskinesia, γ-Vinyl GABA",
author = "S{\o}ren Korsgaard and Daniel Casey and Jes Gerlach",
year = "1983",
doi = "10.1016/0165-1781(83)90014-8",
language = "English (US)",
volume = "8",
pages = "261--269",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "4",

}

TY - JOUR

T1 - Effect of gamma-vinyl GABA in tardive dyskinesia

AU - Korsgaard, Søren

AU - Casey, Daniel

AU - Gerlach, Jes

PY - 1983

Y1 - 1983

N2 - γ-Vinyl GABA (γ-aminobutyric acid), a drug that increases brain GABA via GABA transaminase inhibition, was evaluated in a blind, placebo-controlled trial in 10 patients with stable tardive dyskinesia. Drug effects during active treatment (2 to 6 g/day) and during pre- and posttreatment placebo periods were determined by scoring randomly sequenced videotapes of tardive dyskinesia and parkisonian symptoms recorded weekly during standardized examinations. Tardive dyskinesia was significantly reduced, and correlated to increased parkinsonism. Eye blinking rates decreased, but psychiatric symptoms were unchanged during treatment.

AB - γ-Vinyl GABA (γ-aminobutyric acid), a drug that increases brain GABA via GABA transaminase inhibition, was evaluated in a blind, placebo-controlled trial in 10 patients with stable tardive dyskinesia. Drug effects during active treatment (2 to 6 g/day) and during pre- and posttreatment placebo periods were determined by scoring randomly sequenced videotapes of tardive dyskinesia and parkisonian symptoms recorded weekly during standardized examinations. Tardive dyskinesia was significantly reduced, and correlated to increased parkinsonism. Eye blinking rates decreased, but psychiatric symptoms were unchanged during treatment.

KW - parkinsonism

KW - tardive dyskinesia

KW - γ-Vinyl GABA

UR - http://www.scopus.com/inward/record.url?scp=0020522189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020522189&partnerID=8YFLogxK

U2 - 10.1016/0165-1781(83)90014-8

DO - 10.1016/0165-1781(83)90014-8

M3 - Article

C2 - 6136054

AN - SCOPUS:0020522189

VL - 8

SP - 261

EP - 269

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 4

ER -